⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTXR News
Citius Pharmaceuticals Inc. Common
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
prnewswire.com
CTOR
CTXR
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
prnewswire.com
CTOR
CTXR
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
prnewswire.com
CTOR
CTXR
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
prnewswire.com
CTXR
CTOR
CTXR
CTOR
CTXR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
prnewswire.com
CTOR
CTXR
CTOR
CTXR
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
prnewswire.com
CTOR
CTXR
CTOR
CTXR
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
prnewswire.com
CTOR
CTXR
CTOR
CTXR
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
prnewswire.com
CTOR
CTXR
CTOR
CTXR
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
prnewswire.com
CTXR
CTOR